Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 4/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | METAP2 | P50579 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10758 | 1.00 | NOS1 (0.47) | NOS1DYRK1ASIRT2HSP90AA1IDO1 | |
| SCHEMBL14831000 | 0.76 | MAPT (0.47) | NOS1DYRK1AHSP90AA1IDO1CDK2 | |
| SCHEMBL16433147 | 0.73 | ALDH1A1 (0.41) | NOS1DYRK1AHSP90AA1IDO1CDK2 | |
| SCHEMBL30174455 | 0.71 | CCR1 (0.44) | NOS1DYRK1AHSP90AA1IDO1CDK2 | |
| SCHEMBL30327614 | 0.71 | NOS1 (0.47) | NOS1DYRK1AHSP90AA1IDO1CDK2 | |
| SCHEMBL17673803 | 0.71 | FGFR1 (0.41) | NOS1DYRK1AHSP90AA1IDO1CDK2 | |
| SCHEMBL17673782 | 0.71 | NOS1 (0.47) | NOS1DYRK1AHSP90AA1IDO1CDK2 | |
| SCHEMBL20389659 | 0.69 | PLK4 (0.48) | NOS1DYRK1AKDM4EALDH1A1GAA | |
| SCHEMBL29882851 | 0.69 | PLK4 (0.48) | NOS1DYRK1AKDM4EALDH1A1GAA | |
| SCHEMBL12726379 | 0.68 | MAPT (0.39) | NOS1DYRK1AHSP90AA1IDO1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118019743-A | Compounds useful as SHP2 inhibitors, methods of preparation and uses thereof | 甘李药业股份有限公司 | 2024-05-10 | — | — | CN | claimed |
| WO-2025243046-A1 | COMPOUNDS | Pheno Therapeutics Limited (GB) | 2025-11-27 | — | — | WO | disclosed |
| WO-2025243044-A1 | COMPOUNDS | Pheno Therapeutics Limited (GB) | 2025-11-27 | — | — | WO | disclosed |
| US-20250221988-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI), INC. (CN) | 2025-07-10 | — | — | US | disclosed |
| CN-120058697-A | Bicyclic heterocyclic compounds, preparation method and medical application thereof | 华润医药研究院（深圳）有限公司 | 2025-05-30 | — | — | CN | disclosed |
| EP-4558495-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | Bristol-Myers Squibb Company (US) | 2025-05-28 | — | — | EP | disclosed |
| WO-2025106949-A1 | WRN INHIBITORS | RADD PHARMACEUTICALS, INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| CN-119899172-A | KIF18A inhibitor and application thereof | 轩竹生物科技股份有限公司 | 2025-04-29 | — | — | CN | disclosed |
| CN-119562952-A | KIF18A inhibitors | 山东轩竹医药科技有限公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-119486727-A | Methods and compositions for treating fatty liver and viral infections | 小利兰·斯坦福大学托管委员会 | 2025-02-18 | — | — | CN | disclosed |
| CN-116507326-A | Compounds as GLP-1R agonists | 拓臻制药公司 | 2023-07-28 | — | — | CN | disclosed |
| EP-4204415-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2023-07-05 | — | — | EP | disclosed |
| WO-2023025109-A1 | TOLL-LIKE RECEPTOR INHIBITOR AND PREPARATION AND APPLICATION THEREOF | 上海维申医药有限公司 | 2023-03-02 | — | — | WO | disclosed |
| CN-115667225-A | Compound (I) | 詹森药业有限公司 | 2023-01-31 | — | — | CN | disclosed |
| WO-2022266258-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF IRAK-4 | ARVINAS OPERATIONS, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| CN-115397467-A | Therapeutic agent for tauopathy | 住友制药株式会社 | 2022-11-25 | — | — | CN | disclosed |
| CN-114585609-A | 2H-indazole derivatives and their use in the treatment of diseases | 比奥根MA公司 | 2022-06-03 | — | — | CN | disclosed |
| EP-3990432-A1 | 2H-INDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Biogen MA Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| US-20220089578-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. | 2022-03-24 | — | — | US | disclosed |
| WO-2022042691-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250221988-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | GSPT1, GSS, G6PC1 | NOS1 1108/4885DYRK1A 2883/4885SIRT2 1453/4885 |
| US-20220089578-A1 | COMPOUNDS AS GLP-1R AGONISTS | GLP1R, GIPR, GCGR | NOS1 3565/4885DYRK1A 750/4885SIRT2 1161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.